A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/29/2018
Start Date:November 22, 2016
Contact:Charu Aggarwal, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with
clinical trials showing an approximately 20% durable response in unselected patients with
advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to
accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly
discover and evaluate the utility of blood based biomarkers for use in measuring and
predicting response to immunotherapy in patients with lung cancer.


Inclusion Criteria:

- Advanced Metastatic NSCLC

- Scheduled to initiate an immune checkpoint inhibitor

- Age >= 18 years

- Able to provide informed consent

Exclusion Criteria:

- Other, unrelated, concomitant active, invasive malignancy
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials